WEBULL
News
TCRX
1.000
-2.91%
-0.030
Weekly Report: what happened at TCRX last week (1222-1226)?
Weekly Report · 12/29/2025 09:36
Major Investor Quietly Ramps Up Stake in TScan Therapeutics
TipRanks · 12/24/2025 02:01
Lynx1 Capital Management Reports Acquisition of TScan Therapeutics Common Shares
Reuters · 12/23/2025 23:18
Weekly Report: what happened at TCRX last week (1215-1219)?
Weekly Report · 12/22/2025 09:36
Tracking Baker Brothers Portfolio - Q3 2025 Update
Seeking Alpha · 12/16/2025 14:19
Weekly Report: what happened at TCRX last week (1208-1212)?
Weekly Report · 12/15/2025 09:39
Analysts Offer Insights on Healthcare Companies: Terns Pharmaceuticals (TERN) and TScan Therapeutics (TCRX)
TipRanks · 12/09/2025 12:40
TScan Therapeutics: Overcoming Manufacturing Setbacks with Strategic Adjustments and Promising Potential in Myeloid Malignancies
TipRanks · 12/09/2025 10:26
Promising Potential of TScan Therapeutics’ TSC-101: Analyst Recommends Buy Rating
TipRanks · 12/08/2025 16:35
Weekly Report: what happened at TCRX last week (1201-1205)?
Weekly Report · 12/08/2025 09:39
TScan Therapeutics Announced Saturday, Updated Data from the ALLOHA Phase 1 Heme Trial; 3/3 Of TSC-101-treated Patients Who Reached Two-year Follow-up Remained Relapse-free Vs. 1/4 In Control Arm
Benzinga · 12/07/2025 22:49
TScan Therapeutics announces updated data from ALLOHA Phase 1 trial
TipRanks · 12/07/2025 18:30
TScan Therapeutics Reports Positive Phase 1 Results for TSC-101 in Heme Malignancies
Reuters · 12/06/2025 22:30
TSCAN THERAPEUTICS ANNOUNCES POSITIVE UPDATED DATA FROM THE ALLOHA™ PHASE 1 HEME TRIAL AT THE 67TH AMERICAN SOCIETY OF HEMATOLOGY ANNUAL MEETING AND EXPOSITION
Reuters · 12/06/2025 22:30
TScan Therapeutics Announces Positive Updated Data from the ALLOHA™ Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition
Barchart · 12/06/2025 16:30
TScan Therapeutics To Provide Update On Phase 1 Trial Of TSC-101 In Heme Malignancies Next Week
NASDAQ · 12/04/2025 09:30
TScan Therapeutics Announces Updated ALLOHA Phase 1 Trial Data and Plans for Pivotal Study in 2026
Reuters · 12/03/2025 21:05
TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Future Market Opportunities
Barchart · 12/03/2025 15:05
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 12/03/2025 12:05
After-Hours Biotech Rally: Clene Surges Ahead Of ALS Update; Werewolf, Biomea, Dyne Also Climb
NASDAQ · 12/03/2025 04:34
More
Webull provides a variety of real-time TCRX stock news. You can receive the latest news about Tscan Therapeutics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About TCRX
TScan Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to prevent relapse following allogeneic hematopoietic cell transplantation. The Company is also developing multiple TCR-T therapy product candidates for the treatment of solid tumors. The Company has developed and continues to build its ImmunoBank with TCRs across different targets and human leukocyte antigens types to enable customized multiplex TCR-T therapy. Its solid tumors programs include TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204. Its hematologic malignancies programs include TSC-100, TSC-101, and TSC-102.